News

Trubion Pharmaceuticals has posted revenue for the second quarter $4.1 million, compared to $4.5 million for the same period an year ago. For the six month ended period,

Chesson Labs has received 510(k) market clearance from the FDA for NUVADERM, the company’s liquid bandage product. The FDA has cleared claims on the product to cover intact

Celgene has announced the presentation of final results from two company-sponsored studies of Amrubicin in relapsed small cell lung cancer (SCLC) at the 13th World Conference on Lung

Radius Health (Radius) has announced topline Phase 2 data demonstrating that in women with osteoporosis, BA058, the company’s novel PTHrP (parathyroid hormone-related protein) analog-significantly increased bone mineral density

Ceregene has announced that the Michael J Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company’s Phase 2 trial of CERE-120

Daiichi Sankyo and Eli Lilly have announced that Effient (prasugrel), a new antiplatelet medicine, is now available in pharmacies across the US. The FDA approved Effient tablets is

Merge Healthcare has completed a project to integrate its radiology picture archiving and communications system (PACS) with an electronic health record (EHR) solution from Epic. The new platform

NewCardio has announced that Dedicated Phase I has signed a Master Services Agreement (MSA) with NewCardio. Under terms of the agreement, Dedicated Phase I will receive a license

Genzyme has received approval from the European Commission for the marketing authorization of Mozobil (plerixafor injection). It is likely to provide a new option for patients with blood